摘要
目的探讨替吉奥治疗卵巢癌术后化疗后生化复发患者的疗效及安全性。方法 60例卵巢癌术后化疗后生化复发患者,随机分成治疗组及对照组,各30例。治疗组给予替吉奥治疗,对照组给予观察随访,两组患者均在出现临床症状体征或占位病灶时出组。比较分析两组患者无进展生存时间(PFS)及生存质量情况。结果治疗组糖类抗原125(CA125)下降率(46.7%)及KPS评分增加>10分率(60.0%)均高于对照组(20.0%、13.3%),差异均具有统计学意义(χ~2=4.80、14.07,P<0.05)。治疗组中位无进展生存时间8个月长于对照组中位无进展生存时间4个月。结论替吉奥单药治疗卵巢癌术后化疗后生化复发疗效肯定,同时能提高生存质量,且毒副作用小,值得推广。
Objective To explore the curative effect and security of tegafur, gimeracil and oteracil potassium in the treatment of biochemical recurrent ovarian cancer patients after chemotherapy. Methods A total of 60 biochemical recurrent ovarian cancer patients after chemotherapy were randomly divided into treatment group and control group, with 30 cases in each group. The treatment group received tegafur, gimeracil and oteracil potassium fro treatment, and the control group received follow-up observation. Patients would be taken out of group once clinical symptoms and signs or placeholder lesions appeared in two groups. Comparison and analysis were made on progression-free survival (PFS) time and quality of life in two groups. Results The treatment group had higher carbohydrate antigen 125 (CA125) decline rate (46.7%) and KPS score increasing > 10 points rate (60.0%) than the control group (20.0% and 13.3%), and their difference had statistical significance (χ2=4.80,14.07, P<0.05). The treatment group had longer median progression-free survival time as 8 months than 4 months in the control group. Conclusion Tegafur, gimeracil and oteracil potassium shows affirmative curative effect for the treatment of biochemical recurrent ovarian cancer after chemotherapy, and it also can improve the quality of life with little adverse reactions. It is worth promoting.
作者
陈婵娟
林云笑
陈昌南
潘岐作
谢峰
钟文杰
谭斌
CHEN Chan-juan;LIN Yun-xiao;CHEN Chang-nan(Department of Oncology, Xinhui District People’s Hospital, Jiangmen 529000, China)
出处
《中国现代药物应用》
2017年第5期87-88,共2页
Chinese Journal of Modern Drug Application
基金
2015年度江门市卫生计生局科研项目和新技术新项目推广(项目编号:15A004)
关键词
替吉奥
卵巢癌
糖类抗原125
无进展生存时间
生活质量
Tegafur, gimeracil and oteracil potassium
Ovarian cancer
Carbohydrate antigen 125
Progression-free survival time
Quality of life
